Report cover image

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market - 2025-2033

Publisher DataM Intelligence 4Market Research LLP
Published Apr 02, 2026
Length 186 Pages
SKU # DTAM21122473

Description

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market Overview:
The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market was valued at US$ 8.56 Billion in 2025 and is anticipated to reach US$ 31.76 Billion by 2033, at a CAGR of 0.177 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market.

This report delivers a comprehensive overview of the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market. The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market Scope:
By Drug Class
• Thyroid Hormone Receptor-β (THR-β) Agonists
• Peroxisome Proliferator-Activated Receptor (PPAR) Agonists
• GLP-1 Receptor Agonists
• GLP-1 / Glucagon Dual Receptor Agonists
• Fibroblast Growth Factor 21 (FGF21) Analogues
• Acetyl-CoA Carboxylase (ACC) Inhibitors
• Others

By Fibrosis Stage
• F0–F1
• F2–F3
• F4

By Age Group
• Adults
• Geriatrics
• Pediatrics

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Key Players
• Madrigal Pharmaceuticals, Inc.
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Akero Therapeutics, Inc.
• 89bio, Inc.
• Inventiva
• Sagimet Biosciences Inc.
• Viking Therapeutics
• CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
• Gilead Sciences, Inc. .

Major Highlights
This report delivers a comprehensive overview of the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market. The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

186 Pages
1. Definition and Overview
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. Executive Summary
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Global Burden of Obesity and Metabolic Syndrome
3.1.1.2. Advancements in Drug Development and Clinical Research
3.1.1.3. Increasing Awareness and Diagnosis of Liver Diseases
3.1.2. Restraints
3.1.2.1. Lack of Widely Approved and Effective Therapies
3.1.2.2. High Treatment Costs and Limited Reimbursement
3.1.2.3. Stringent Regulatory Requirements for Drug Approval
3.1.3. Opportunity
3.1.3.1. Growing Demand for Effective Therapies for Untreated MASH Population
3.1.3.2. Increasing Adoption of Precision Medicine and Targeted Therapies
3.1.4. Trends
3.1.4.1. Expansion of GLP-1-Based Therapeutic Approaches
3.1.4.2. Rising Clinical Trials and Strong Drug Development Pipeline
3.1.5. Impact Analysis
4. Industry Analysis
4.1. Porter's Five Force Analysis – Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market
4.2. Geopolitical & Supply Chain Exposure
4.2.1. API sourcing concentration for MASH drug development and manufacturing
4.2.2. Trade policies, export controls, and pharmaceutical supply chain risks
4.3. Social & Patient-Centric Factors
4.3.1. Physician prescribing behavior in metabolic and liver disease treatment
4.3.2. Patient adherence challenges in long-term metabolic and liver disease therapies
4.3.3. Treatment switching patterns between metabolic and liver disease therapies
4.3.4. Awareness gaps and underdiagnosis of MASH among at-risk populations
4.4. Economic Factors
4.4.1. Healthcare expenditure and reimbursement policies for MASH therapies
4.4.2. Rising R&D costs and manufacturing expenses for innovative liver disease drugs
4.4.3. Economic burden of metabolic disorders and impact on treatment demand
4.5. Pricing Analysis
4.5.1. Pricing dynamics of innovative MASH therapies and emerging treatment options
4.6. Regulatory Analysis
4.6.1. Regulatory approval pathways for MASH drug candidates
4.6.2. Post-marketing surveillance and pharmacovigilance requirements
4.6.3. GMP compliance and regulatory inspection risks in pharmaceutical manufacturing
4.6.4. Regulatory alignment across major agencies, including FDA, EMA, PMDA, NMPA, and CDSCO
4.7. Go-To-Market (GTM) Strategy
4.7.1. Hospital, specialty clinic, and hepatology network penetration strategies
4.8. Innovation & R&D Trends
4.8.1. Development of next-generation metabolic and anti-fibrotic therapies
4.8.2. Combination therapy strategies targeting metabolic dysfunction and liver fibrosis
4.9. Sustainability and ESG Analysis
4.9.1. Responsible sourcing of pharmaceutical ingredients and sustainable manufacturing practices
4.10. Ecosystem Participants
4.10.1. Branded MASH drug developers and pharmaceutical companies
4.10.2. Biotechnology firms developing novel metabolic and liver disease therapies
4.10.3. API and pharmaceutical ingredient suppliers
4.10.4. Contract research, manufacturing, and packaging organizations
4.10.5. Healthcare providers, distributors, and specialty pharmacy networks
4.11. Buyer Decision Criteria & Adoption Drivers
4.11.1. Clinical efficacy and safety profile of emerging MASH therapies
4.11.2. Regulatory approval status and clinical evidence
4.11.3. Pricing, reimbursement, and patient access programs
4.11.4. Treatment outcomes and long-term disease management benefits
4.12. DMI Opinion – Strategic Outlook for the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market
5. By Drug Class
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
5.1.2. Market Attractiveness Index, By Drug Class
5.2. Thyroid Hormone Receptor-β (THR-β) Agonists*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Resmetirom
5.2.4. VK2809
5.3. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists
5.3.1. Lanifibranor
5.4. GLP-1 Receptor Agonists
5.4.1. Semaglutide
5.5. GLP-1 / Glucagon Dual Receptor Agonists
5.5.1. Survodutide
5.6. Fibroblast Growth Factor 21 (FGF21) Analogues
5.6.1. Pegozafermin
5.6.2. Efruxifermin
5.7. Acetyl-CoA Carboxylase (ACC) Inhibitors
5.7.1. Denifanstat
5.8. Others
6. By Fibrosis Stage
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
6.1.2. Market Attractiveness Index, By Fibrosis Stage
6.2. F0–F1*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. F2–F3
6.4. F4
7. By Age Group
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
7.1.2. Market Attractiveness Index, By Age Group
7.2. Adults*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Geriatrics
7.4. Pediatrics
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Ambulatory Surgical Centers
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.8.1. US
10.2.8.2. Canada
10.2.8.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.8.1. Germany
10.3.8.2. United Kingdom
10.3.8.3. France
10.3.8.4. Italy
10.3.8.5. Spain
10.3.8.6. Netherlands
10.3.8.7. Switzerland
10.3.8.8. Sweden
10.3.8.9. Norway
10.3.8.10. Denmark
10.3.8.11. Belgium
10.3.8.12. Poland
10.3.8.13. Austria
10.3.8.14. Ireland
10.3.8.15. Portugal
10.3.8.16. Greece
10.3.8.17. Finland
10.3.8.18. Rest of Europe
10.4. Latin America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.8.1. Brazil
10.4.8.2. Argentina
10.4.8.3. Mexico
10.4.8.4. Chile
10.4.8.5. Colombia
10.4.8.6. Peru
10.4.8.7. Rest of Latin America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.8.1. China
10.5.8.2. Japan
10.5.8.3. India
10.5.8.4. South Korea
10.5.8.5. Australia
10.5.8.6. New Zealand
10.5.8.7. Singapore
10.5.8.8. Malaysia
10.5.8.9. Thailand
10.5.8.10. Indonesia
10.5.8.11. Vietnam
10.5.8.12. Philippines
10.5.8.13. Taiwan
10.5.8.14. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.6.8.1. Saudi Arabia
10.6.8.2. United Arab Emirates
10.6.8.3. Qatar
10.6.8.4. Kuwait
10.6.8.5. Oman
10.6.8.6. Bahrain
10.6.8.7. South Africa
10.6.8.8. Egypt
10.6.8.9. Nigeria
10.6.8.10. Morocco
10.6.8.11. Rest of Middle East & Africa
11. Competitive Landscape Analysis
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
11.4. Partner Identification Analysis
11.5. Investment & Funding Landscape
11.6. Strategic Alliances & Innovation Pipelines
12. Company Profiles
12.1. Madrigal Pharmaceuticals, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.3. Revenue Analysis
12.1.4. Pricing Analysis
12.1.5. SWOT Analysis
12.1.6. Recent Developments
12.1.6.1. Major Deals
12.1.6.2. M&A
12.1.6.3. Collaboration
12.1.6.4. Acquisition
12.1.6.5. Joint Ventures
12.1.6.6. Innovations
12.1.7. Recent News
12.1.7.1. Events
12.1.7.2. Conferences
12.1.7.3. Symposiums
12.1.7.4. Webinars
12.2. Novo Nordisk A/S
12.3. Boehringer Ingelheim International GmbH
12.4. Akero Therapeutics, Inc.
12.5. 89bio, Inc.
12.6. Inventiva
12.7. Sagimet Biosciences Inc.
12.8. Viking Therapeutics
12.9. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
12.10. Gilead Sciences, Inc. . (LIST NOT EXHAUSTIVE)
13. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market – Research Methodology
13.1. Research Data
13.1.1. Secondary Data
13.1.2. Primary Data
13.1.3. CAGR Analysis
13.2. Market Size Estimation Methodology
13.2.1. Bottom-Up Approach
13.2.2. Top-Down Approach
13.3. Market Breakdown & Data Triangulation
13.4. Research Assumptions
13.5. Limitations
14. Appendix
14.1. About Us and Services
14.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us